Exploratory secondary analysis of MINDACT: in 868 women over 50 with clinical high/genomic low-risk HR+ HER2− early breast cancer, 8-year DMFS without chemotherapy was 87.9–91.3% across high-risk subgroups; absolute chemotherapy benefit was −2.2% to 1.2%.
Secondary analysisn = 868
Gielen et al. 70-gene signature MammaPrint for early-stage HR-positive, HER2-negative breast cancer: Outcome in the MINDACT trial for key clinical-pathological high-risk subgroups